NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
11/06/2024
Back to search
Official data from USPTO
EXONDYS 51 ETEPLIRSEN INJECTION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
11/06/2024
Trademark type
Combined
Nice classes
44
Filing date
10/23/2017
Registration date
06/12/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/06/2024
Last transaction
11/06/2024
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
12/09/2016
First use in commerce
12/09/2016
Drawing code
3
Owner type
03
Owner location
Cambridge, MA, US
Examiner
CLYBURN, CARLA DIONNE
Current location
Historical data usage
Mark description
The mark consists of a hexagon, bisected by a swoosh, followed by the text and numeral "EXONDYS 51" over the text (eteplirsen) Injection; the color gray is intended to show shading or contrast only.
Holders and representatives
Holders
Sarepta Therapeutics, Inc.
Representatives
Maury M. Tepper, III TEPPER & EYSTER, PLLC
Technical classification
Nice Classes
Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 44
Providing health information
Publications
History of USPTO decisions and trademark events.
23 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
11/06/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/06/2024
E815
TEAS SECTION 8 & 15 RECEIVED
05/17/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/12/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
01/22/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
06/12/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/27/2018
PUBO
PUBLISHED FOR OPPOSITION
03/27/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/07/2018
ALIE
ASSIGNED TO LIE
02/22/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/09/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
02/09/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/09/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
02/09/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/09/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/08/2018
GNRT
NON-FINAL ACTION E-MAILED
02/08/2018
CNRT
NON-FINAL ACTION WRITTEN
02/08/2018
DOCK
ASSIGNED TO EXAMINER
01/31/2018
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/02/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/01/2017
NWAP
NEW APPLICATION ENTERED
10/26/2017
Continuous trademark protection
Get notified about every new filing that threatens EXONDYS 51 ETEPLIRSEN INJECTION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.